No Detail Found!

Safety of oral itraconazole in the treatment of seborrheic dermatitis

Author(s)
Lubna Khondker Department of Medical Statistics, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Md Abdul Wahab Department of Dermatology and Venereology, Bangabandhu Sheikh Mujib Medical University, Dhaka Bangladesh.
Md Shirajul Islam Khan Department of Dermatology and Venereology, Combined Military Hospital, Dhaka Bangladesh.
Sonia Shirin Department of community Medicine, Ibrahim Medical College, BIRDEM, Dhaka, Bangladesh.
Abstract
Background Seborrheic dermatitis (SD) is a chronic, papulosquamous dermatosis and Malassezia yeasts are considered as causative factors. The dual antifungal and anti-inflammatory effects of oral itraconazole account for its prolonged therapeutic action in SD. Objectives: To assess the safety of oral itraconazole in the treatment of seborrheic dermatitis. Patients and methods During a period of total 2 years from January, 2008 to December, 2009, 37 patients of SD were treated with oral itraconazole (200 mg/day for 7 days) in first month and consecutive use of 200 mg/day for the first 2 days of the following 11 months. Patients were followed up monthly for clinical side effects and biochemical derangements. Results 16 (43.2%) patients suffered from different side effects of drug i.e. nausea in 16 (76.2%) patients, followed by abdominal pain in 3 (14.3%) and diarrhea in 2 (9.5%). These were selflimiting and did not warrant discontinuation of therapy. Biochemical abnormalities were not seen in any patient. Conclusion The study suggests that oral itraconazole is a safe treatment option of seborrheic dermatitis.
Publication Details
Page(s) 102-105
DOI DOI not available
Published Journal: Journal of Pakistan Association of Dermatologists, Volume: 21, Issue: 2, Year: 2011

Request the full text from PASTIC

Keywords
Safety, Itraconazole, seborrheic dermatitis
0

Citations

0

Downloads

44

Views